Monte Rosa Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Monte Rosa Therapeutics (GLUE).

Price Target Range — 10 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingOverweight# Analysts6Avg. Consensus PT$25Upside to Avg. PT+80.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 25, 2026	Guggenheim	Michael Schmidt	Maintained	Buy	$28
Aug 7, 2026	JP Morgan	Brian Cheng	PT Cut	Overweight	$31→$27
Aug 7, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$35→$28
Aug 7, 2026	Wells Fargo	Derek Archila	PT Cut	Overweight	$29→$27
Aug 3, 2026	Wedbush	Robert Driscoll	PT Cut	Outperform	$37→$27
Jun 30, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$30→$35
May 11, 2026	JP Morgan	Brian Cheng	PT Raise	Overweight	$30→$31
Mar 18, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$34→$30
Mar 18, 2026	Wells Fargo	Derek Archila	PT Cut	Overweight	$30→$29
Jan 14, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$28→$37
Jan 8, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$22→$30
Jan 8, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$16→$34
Dec 16, 2025	Wells Fargo	Derek Archila	Upgrade	Equal-Weight→Overweight	$13→$22
Nov 7, 2025	Wells Fargo	Derek Archila	PT Raise	Equal-Weight	$10→$13
Mar 21, 2025	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$11→$10
Mar 21, 2025	Wedbush	Robert Driscoll	PT Raise	Outperform	$15→$17
Mar 12, 2025	LifeSci Capital	—	Initiate	Outperform	$19
Dec 19, 2024	Wells Fargo	Derek Archila	Downgrade	Overweight→Equal-Weight	$14→$11
Nov 8, 2024	Wells Fargo	Derek Archila	PT Cut	Overweight	$17→$14
Sep 12, 2024	Wedbush	Robert Driscoll	Maintained	Outperform	$11

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $28 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $31 to $27.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28

Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $35 to $28.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $29 to $27.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27

Wedbush analyst Robert Driscoll maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and lowers the price target from $37 to $27.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35

Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $30 to $35.

Benzinga Newsdesk

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

PRO
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

PRO
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28

PRO
Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

PRO
Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27

PRO
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35

People Also Watch

People Also Watch

Benzinga

Benzinga

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

PROJP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

PROGuggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28

PROWells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

PROWedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27

PROGuggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35

People Also Watch

People Also Watch

PRO
Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

PRO
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

PRO
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28

PRO
Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

PRO
Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27

PRO
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35